According to previous studies, overexpression of BIRC6 is associated with higher cell proliferation, poorer prognosis, and worse clinical findings at the time of cancer diagnosis [15], in which we can point to the investigation of the role of BIRC6 in colorectal cancer [15], hepatocellular cancer [16], non-small-cell lung cancer [11], epithelial ovarian cancer [17], prostate cancer [18], lung tissue cancers [19], esophageal squamous cell carcinoma [20, 21], gastric carcinoma [22], acute leukemia, and acute myeloblastic leukemia [23]. This evidence concerns the gene BIRC6 and Familial prostate cancer.